Cumberland Total Liab vs Long Term Debt Analysis

CPIX Stock

USD 1.48 0.03 2.07%

Cumberland Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cumberland Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cumberland Pharmaceuticals is a good investment. Please check the relationship between Cumberland Pharmaceuticals Total Liab and its Long Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

Total Liab vs Long Term Debt

Total Liab vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cumberland Pharmaceuticals Total Liab account and Long Term Debt. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cumberland Pharmaceuticals' Total Liab and Long Term Debt is 0.96. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of Cumberland Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cumberland Pharmaceuticals' Total Liab and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Cumberland Pharmaceuticals are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Liab i.e., Cumberland Pharmaceuticals' Total Liab and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.96

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Long Term Debt

Long-term debt is a debt that Cumberland Pharmaceuticals has held for over one year. Long-term debt appears on Cumberland Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Cumberland Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most indicators from Cumberland Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cumberland Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.Discontinued Operations is likely to rise to about 2.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 8.9 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	98.0K	586.0K	667.9K	701.3K
Depreciation And Amortization	6.8M	5.4M	5.8M	6.1M

Interest Expense Depreciation And Amortization

Cumberland Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Non Currrent Assets Other	Other Liab
Total Assets		0.39	0.53	0.48	0.64	0.09	0.87	-0.23	0.39	0.33	0.5	0.49	0.5	0.49	0.1	0.37	0.54	0.57	-0.09	0.43	0.05	0.75	0.17	0.66	0.18	0.13
Short Long Term Debt Total	0.39		0.7	0.92	-0.44	0.6	0.38	0.69	-0.59	0.83	-0.39	0.87	-0.53	0.75	-0.65	0.99	0.58	0.64	0.17	0.98	0.53	-0.22	-0.22	0.76	0.77	0.89
Other Current Liab	0.53	0.7		0.87	-0.14	0.4	0.49	0.45	-0.25	0.62	-0.26	0.73	-0.26	0.74	-0.47	0.71	0.64	0.5	0.25	0.79	0.35	0.04	-0.14	0.82	0.34	0.57
Total Current Liabilities	0.48	0.92	0.87		-0.34	0.55	0.48	0.67	-0.46	0.86	-0.42	0.93	-0.48	0.82	-0.7	0.92	0.58	0.58	0.33	0.97	0.49	-0.17	-0.12	0.9	0.69	0.81
Total Stockholder Equity	0.64	-0.44	-0.14	-0.34		-0.38	0.53	-0.82	0.85	-0.38	0.87	-0.29	0.96	-0.18	0.68	-0.47	0.02	0.05	-0.3	-0.42	-0.36	0.94	0.33	-0.05	-0.43	-0.61
Property Plant And Equipment Net	0.09	0.6	0.4	0.55	-0.38		0.41	0.63	-0.76	0.72	-0.39	0.54	-0.48	0.54	-0.62	0.53	-0.02	0.31	0.13	0.55	0.99	-0.31	-0.41	0.3	0.79	0.7
Current Deferred Revenue	0.87	0.38	0.49	0.48	0.53	0.41		-0.1	0.14	0.5	0.4	0.5	0.38	0.51	-0.09	0.33	0.28	0.57	-0.05	0.4	0.41	0.6	0.1	0.57	0.39	0.22
Net Debt	-0.23	0.69	0.45	0.67	-0.82	0.63	-0.1		-0.85	0.74	-0.91	0.64	-0.93	0.4	-0.93	0.69	0.26	0.06	0.56	0.7	0.6	-0.74	-0.4	0.48	0.71	0.88
Retained Earnings	0.39	-0.59	-0.25	-0.46	0.85	-0.76	0.14	-0.85		-0.63	0.73	-0.39	0.87	-0.35	0.76	-0.58	-0.03	-0.16	-0.18	-0.54	-0.75	0.74	0.46	-0.13	-0.69	-0.8
Accounts Payable	0.33	0.83	0.62	0.86	-0.38	0.72	0.5	0.74	-0.63		-0.46	0.8	-0.53	0.73	-0.84	0.8	0.42	0.53	0.34	0.84	0.7	-0.23	-0.07	0.71	0.81	0.86
Cash	0.5	-0.39	-0.26	-0.42	0.87	-0.39	0.4	-0.91	0.73	-0.46		-0.42	0.95	-0.15	0.81	-0.42	-0.06	0.25	-0.65	-0.43	-0.37	0.88	0.39	-0.27	-0.47	-0.63
Non Current Assets Total	0.49	0.87	0.73	0.93	-0.29	0.54	0.5	0.64	-0.39	0.8	-0.42		-0.47	0.75	-0.68	0.87	0.42	0.49	0.37	0.92	0.47	-0.21	-0.18	0.91	0.8	0.77
Cash And Short Term Investments	0.5	-0.53	-0.26	-0.48	0.96	-0.48	0.38	-0.93	0.87	-0.53	0.95	-0.47		-0.27	0.82	-0.55	-0.06	0.05	-0.44	-0.53	-0.46	0.92	0.39	-0.25	-0.59	-0.73
Net Receivables	0.49	0.75	0.74	0.82	-0.18	0.54	0.51	0.4	-0.35	0.73	-0.15	0.75	-0.27		-0.46	0.74	0.33	0.67	0.04	0.79	0.46	-0.02	-0.01	0.68	0.57	0.55
Common Stock Shares Outstanding	0.1	-0.65	-0.47	-0.7	0.68	-0.62	-0.09	-0.93	0.76	-0.84	0.81	-0.68	0.82	-0.46		-0.65	-0.21	-0.21	-0.58	-0.68	-0.61	0.62	0.13	-0.57	-0.73	-0.82
Non Current Liabilities Total	0.37	0.99	0.71	0.92	-0.47	0.53	0.33	0.69	-0.58	0.8	-0.42	0.87	-0.55	0.74	-0.65		0.61	0.62	0.18	0.98	0.46	-0.25	-0.24	0.76	0.73	0.89
Inventory	0.54	0.58	0.64	0.58	0.02	-0.02	0.28	0.26	-0.03	0.42	-0.06	0.42	-0.06	0.33	-0.21	0.61		0.36	0.09	0.61	-0.05	0.28	-0.1	0.64	0.09	0.51
Other Current Assets	0.57	0.64	0.5	0.58	0.05	0.31	0.57	0.06	-0.16	0.53	0.25	0.49	0.05	0.67	-0.21	0.62	0.36		-0.38	0.62	0.27	0.26	0.24	0.49	0.34	0.37
Other Stockholder Equity	-0.09	0.17	0.25	0.33	-0.3	0.13	-0.05	0.56	-0.18	0.34	-0.65	0.37	-0.44	0.04	-0.58	0.18	0.09	-0.38		0.25	0.13	-0.38	0.01	0.4	0.26	0.29
Total Liab	0.43	0.98	0.79	0.97	-0.42	0.55	0.4	0.7	-0.54	0.84	-0.43	0.92	-0.53	0.79	-0.68	0.98	0.61	0.62	0.25		0.49	-0.22	-0.19	0.84	0.73	0.87
Property Plant And Equipment Gross	0.05	0.53	0.35	0.49	-0.36	0.99	0.41	0.6	-0.75	0.7	-0.37	0.47	-0.46	0.46	-0.61	0.46	-0.05	0.27	0.13	0.49		-0.29	-0.38	0.24	0.75	0.66
Total Current Assets	0.75	-0.22	0.04	-0.17	0.94	-0.31	0.6	-0.74	0.74	-0.23	0.88	-0.21	0.92	-0.02	0.62	-0.25	0.28	0.26	-0.38	-0.22	-0.29		0.33	0.05	-0.4	-0.43
Short Term Debt	0.17	-0.22	-0.14	-0.12	0.33	-0.41	0.1	-0.4	0.46	-0.07	0.39	-0.18	0.39	-0.01	0.13	-0.24	-0.1	0.24	0.01	-0.19	-0.38	0.33		-0.01	-0.35	-0.44
Intangible Assets	0.66	0.76	0.82	0.9	-0.05	0.3	0.57	0.48	-0.13	0.71	-0.27	0.91	-0.25	0.68	-0.57	0.76	0.64	0.49	0.4	0.84	0.24	0.05	-0.01		0.54	0.62
Non Currrent Assets Other	0.18	0.77	0.34	0.69	-0.43	0.79	0.39	0.71	-0.69	0.81	-0.47	0.8	-0.59	0.57	-0.73	0.73	0.09	0.34	0.26	0.73	0.75	-0.4	-0.35	0.54		0.83
Other Liab	0.13	0.89	0.57	0.81	-0.61	0.7	0.22	0.88	-0.8	0.86	-0.63	0.77	-0.73	0.55	-0.82	0.89	0.51	0.37	0.29	0.87	0.66	-0.43	-0.44	0.62	0.83

Click cells to compare fundamentals

Cumberland Pharmaceuticals Account Relationship Matchups

Cumberland Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Short Long Term Debt Total	21.5M	17.1M	16.1M	21.0M	18.4M	11.9M
Other Current Liab	7.7M	11.3M	8.7M	17.6M	13.6M	7.8M
Total Current Liabilities	24.2M	25.7M	19.3M	28.6M	28.0M	16.8M
Total Stockholder Equity	51.1M	47.0M	42.8M	36.3M	29.6M	58.3M
Property Plant And Equipment Net	3.7M	2.6M	1.5M	5.5M	7.0M	7.4M
Net Debt	(6.7M)	(7.7M)	(11.0M)	1.2M	106.9K	112.2K
Retained Earnings	1.2M	(2.1M)	(5.6M)	(11.2M)	(17.5M)	(16.6M)
Accounts Payable	10.0M	13.4M	9.6M	10.8M	14.0M	14.7M
Cash	28.2M	24.8M	27.0M	19.8M	18.3M	27.3M
Non Current Assets Total	54.4M	46.5M	38.8M	47.1M	46.1M	27.5M
Cash And Short Term Investments	28.2M	24.8M	27.0M	19.8M	18.3M	31.1M
Net Receivables	7.9M	12.4M	6.9M	13.2M	9.8M	7.4M
Common Stock Shares Outstanding	15.4M	15.2M	14.9M	14.6M	14.3M	13.5M
Liabilities And Stockholders Equity	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Non Current Liabilities Total	29.3M	23.9M	22.6M	28.4M	24.5M	13.1M
Inventory	8.9M	10.6M	8.4M	9.4M	4.6M	7.3M
Other Current Assets	2.8M	2.2M	3.3M	3.5M	3.0M	2.3M
Other Stockholder Equity	2.9M	3.1M	3.4M	(212.3K)	(244.2K)	(256.4K)
Total Liab	53.5M	49.6M	41.9M	57.0M	52.5M	29.9M
Property Plant And Equipment Gross	3.7M	2.6M	1.5M	5.5M	9.3M	9.7M
Total Current Assets	50.2M	50.0M	45.7M	45.9M	35.7M	60.5M
Intangible Assets	30.9M	28.1M	24.0M	30.6M	22.6M	19.2M
Non Currrent Assets Other	18.9M	14.9M	12.5M	10.0M	15.5M	16.3M
Other Liab	8.7M	7.9M	7.5M	7.6M	8.7M	9.2M
Other Assets	18.9M	17.8M	12.5M	10.0M	11.6M	7.4M
Long Term Debt	20M	18.5M	15M	16.2M	12.8M	9.3M
Common Stock	49.9M	49.1M	48.5M	47.5M	47.1M	44.7M
Property Plant Equipment	16.3M	12.2M	1.5M	5.5M	6.3M	6.6M
Net Tangible Assets	19.3M	18.0M	18.0M	4.8M	4.3M	4.1M
Noncontrolling Interest In Consolidated Entity	(198.6K)	(274.3K)	(37.6K)	(117.1K)	(105.4K)	(110.7K)
Common Stock Total Equity	52.4M	51.1M	49.9M	49.1M	44.2M	46.2M
Retained Earnings Total Equity	11.7M	4.7M	1.2M	(2.1M)	(1.9M)	(1.8M)
Long Term Debt Total	9.8M	20M	18.5M	15M	17.3M	10.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Cumberland Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cumberland Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cumberland Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cumberland Pharmaceuticals Stock:

How To Invest In Cumberland

Details

Is Cumberland Stock a good investment?

Details

What is Cumberland Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Cumberland Stock analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like

Is Cumberland Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. If investors know Cumberland will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cumberland Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.59)

Revenue Per Share

2.728

Quarterly Revenue Growth

(0.08)

Return On Assets

(0.05)

Return On Equity

(0.27)

The market value of Cumberland Pharmaceuticals is measured differently than its book value, which is the value of Cumberland that is recorded on the company's balance sheet. Investors also form their own opinion of Cumberland Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cumberland Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cumberland Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cumberland Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cumberland Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cumberland Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cumberland Total Liab vs Long Term Debt Analysis

Total Liab vs Long Term Debt

Total Liab vs Long Term Debt Correlation Analysis

Correlation Coefficient

Total Liab

Long Term Debt

Cumberland Pharmaceuticals fundamental ratios Correlations

Cumberland Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cumberland Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Cumberland Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Non Current Liabilities Total
Total Liab	+ 0.97	Total Current Liabilities
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity

Common Stock Shares Outstanding	- 0.93	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.91	Net Debt
Retained Earnings	- 0.85	Net Debt
Common Stock Shares Outstanding	- 0.84	Accounts Payable
Other Liab	- 0.82	Common Stock Shares Outstanding